HK1149563A1 - - Google Patents

Info

Publication number
HK1149563A1
HK1149563A1 HK11107570.0A HK11107570A HK1149563A1 HK 1149563 A1 HK1149563 A1 HK 1149563A1 HK 11107570 A HK11107570 A HK 11107570A HK 1149563 A1 HK1149563 A1 HK 1149563A1
Authority
HK
Hong Kong
Application number
HK11107570.0A
Inventor
Rukhsana Tasneem Mohammed
Roger Victor Bonnert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1149563A1 publication Critical patent/HK1149563A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK11107570.0A 2003-05-27 2009-06-30 HK1149563A1 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds
HK09105852.7A HK1126773A1 (xx) 2003-05-27 2009-06-30

Publications (1)

Publication Number Publication Date
HK1149563A1 true HK1149563A1 (xx) 2011-10-07

Family

ID=33492578

Family Applications (3)

Application Number Title Priority Date Filing Date
HK06111158.9A HK1090635A1 (en) 2003-05-27 2006-10-11 Substituted 3-sulfur indoles
HK11107570.0A HK1149563A1 (xx) 2003-05-27 2009-06-30
HK09105852.7A HK1126773A1 (xx) 2003-05-27 2009-06-30

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK06111158.9A HK1090635A1 (en) 2003-05-27 2006-10-11 Substituted 3-sulfur indoles

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09105852.7A HK1126773A1 (xx) 2003-05-27 2009-06-30

Country Status (31)

Country Link
US (4) US7687535B2 (xx)
EP (3) EP2281815B1 (xx)
JP (2) JP4541361B2 (xx)
KR (3) KR20110050754A (xx)
CN (2) CN1795174B (xx)
AR (1) AR044552A1 (xx)
AT (3) ATE502010T1 (xx)
AU (1) AU2004242624B2 (xx)
BR (1) BRPI0410711B8 (xx)
CA (1) CA2526866C (xx)
CO (1) CO5630030A2 (xx)
CY (3) CY1109104T1 (xx)
DE (2) DE602004031894D1 (xx)
DK (3) DK1656346T3 (xx)
ES (3) ES2382606T3 (xx)
HK (3) HK1090635A1 (xx)
HR (3) HRP20090281T1 (xx)
IL (4) IL171928A (xx)
IS (2) IS2722B (xx)
MX (1) MXPA05012680A (xx)
MY (1) MY144483A (xx)
NO (1) NO20056130L (xx)
NZ (1) NZ543722A (xx)
PL (3) PL2025670T3 (xx)
PT (3) PT1656346E (xx)
RU (1) RU2361860C2 (xx)
SE (2) SE0301569D0 (xx)
SI (3) SI2025670T1 (xx)
TW (2) TWI328004B (xx)
WO (1) WO2004106302A1 (xx)
ZA (1) ZA200509598B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
DK1833791T3 (da) 2004-12-27 2011-10-24 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
BRPI0610035A2 (pt) 2005-04-21 2010-05-18 Serono Lab sulfonamidas de pirazina 2,3 substituìdas
ZA200709819B (en) 2005-05-24 2009-09-30 Serono Lab Tricyclic spiro derivatives as CRTH2 modulators
EP1916245B1 (en) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indole derivative having pgd2 receptor antagonist activity
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP2407459A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
EP1928457B1 (en) * 2005-09-30 2012-12-12 Pulmagen Therapeutics (Asthma) Limited Quinolines and their therapeutic use
JP2009538289A (ja) * 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
DK2046740T3 (da) * 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
AU2007282949B8 (en) 2006-08-07 2012-10-04 Actelion Pharmaceuticals Ltd. (3-Amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic acid derivatives
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
NZ581856A (en) * 2007-06-21 2011-05-27 Actimis Pharmaceuticals Inc Amine salts of the CRTH2 antagonist {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid
EP2170838A1 (en) * 2007-06-21 2010-04-07 Actimis Pharmaceuticals, Inc., Particulates of a crth2 antagonist
ATE502920T1 (de) 2007-12-14 2011-04-15 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2010039982A1 (en) * 2008-10-01 2010-04-08 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US8273769B2 (en) 2009-02-12 2012-09-25 Merck Serono Sa Phenoxy acetic acid derivatives
KR101752932B1 (ko) 2009-07-06 2017-07-03 아스트라제네카 아베 4-(아세틸아미노))-3-［(4-클로로-페닐)티오］-2-메틸-1ｈ-인돌-1-아세트산의 중간체 및 그의 제조 방법
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US9032565B2 (en) 2009-12-16 2015-05-19 Kohler Co. Touchless faucet assembly and method of operation
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
TWI562987B (en) 2010-03-22 2016-12-21 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
EP2697223B1 (en) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
AU2013235439B2 (en) 2012-03-21 2017-11-23 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
WO2014055595A1 (en) * 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
PL2970265T3 (pl) * 2013-03-15 2018-11-30 Plexxikon Inc. Heterocykliczne związki i ich zastosowania
US20160194299A1 (en) * 2013-05-24 2016-07-07 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
PL3119779T3 (pl) 2014-03-17 2019-01-31 Idorsia Pharmaceuticals Ltd Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2
JP6484644B2 (ja) 2014-03-18 2019-03-13 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
EP3328500B1 (en) 2015-07-30 2023-04-12 The Trustees of the University of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 antagonists
MX2018003202A (es) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Formas cristalinas.
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
AU6254294A (en) 1993-02-24 1994-09-14 Merck & Co., Inc. Inhibitors of hiv reverse transcriptase
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AR017256A1 (es) 1997-08-21 2001-09-05 American Home Prod Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden
WO1999032112A1 (en) 1997-12-19 1999-07-01 Eli Lilly And Company Method for treating diabetes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
WO2001032621A1 (fr) * 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif
IL150388A0 (en) 1999-12-24 2002-12-01 Aventis Pharma Ltd Azaindoles
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
JP4595182B2 (ja) * 2000-09-07 2010-12-08 ソニー株式会社 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体
US6933316B2 (en) * 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
BR0307406A (pt) 2002-02-01 2004-12-28 Hoffmann La Roche Indóis substituìdos como agonistas alfa-1
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005040114A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
JP2009539782A (ja) 2006-06-08 2009-11-19 ニューロキー エイ／エス 低体温誘導薬剤の使用方法
KR20090023645A (ko) 2006-06-28 2009-03-05 사노피-아벤티스 신규한 ｃｘｃｒ2 억제제

Also Published As

Publication number Publication date
EP2025670A1 (en) 2009-02-18
CO5630030A2 (es) 2006-04-28
IS8920A (is) 2010-08-09
SI2281815T1 (sl) 2012-06-29
DE602004031894D1 (de) 2011-04-28
CY1109104T1 (el) 2014-07-02
WO2004106302A1 (en) 2004-12-09
BRPI0410711B8 (pt) 2021-05-25
CY1112853T1 (el) 2016-02-10
ES2322650T3 (es) 2009-06-24
SE0301569D0 (sv) 2003-05-27
US20090163518A1 (en) 2009-06-25
BRPI0410711B1 (pt) 2018-09-25
IL171928A (en) 2011-06-30
EP1656346A1 (en) 2006-05-17
PT1656346E (pt) 2009-05-20
IS8189A (is) 2005-12-20
TW200510301A (en) 2005-03-16
RU2361860C2 (ru) 2009-07-20
PT2281815E (pt) 2012-05-24
AR044552A1 (es) 2005-09-21
TWI328004B (en) 2010-08-01
ZA200509598B (en) 2006-12-27
EP2281815A1 (en) 2011-02-09
CY1111469T1 (el) 2015-08-05
CN102391171A (zh) 2012-03-28
CA2526866C (en) 2012-10-16
HK1126773A1 (xx) 2009-09-11
AU2004242624B2 (en) 2008-03-13
NO20056130L (no) 2006-02-27
PL2281815T3 (pl) 2012-08-31
EP2025670B1 (en) 2011-03-16
PT2025670E (pt) 2011-05-24
US20120178764A1 (en) 2012-07-12
US20110263614A1 (en) 2011-10-27
ATE425965T1 (de) 2009-04-15
ES2382606T3 (es) 2012-06-11
JP2010155862A (ja) 2010-07-15
HK1090635A1 (en) 2006-12-29
KR101067535B1 (ko) 2011-09-27
MXPA05012680A (es) 2006-02-08
ATE502010T1 (de) 2011-04-15
CN1795174A (zh) 2006-06-28
DK1656346T3 (da) 2009-06-15
DK2025670T3 (da) 2011-06-06
AU2004242624A1 (en) 2004-12-09
BRPI0410711A (pt) 2006-06-13
RU2005137403A (ru) 2006-05-27
IL194872A0 (en) 2011-08-01
ATE552243T1 (de) 2012-04-15
PL2025670T3 (pl) 2011-07-29
JP2007501269A (ja) 2007-01-25
KR20060015303A (ko) 2006-02-16
KR20110051297A (ko) 2011-05-17
SE0302305D0 (sv) 2003-08-27
NZ543722A (en) 2007-05-31
PL1656346T3 (pl) 2009-07-31
DE602004020072D1 (de) 2009-04-30
HRP20120390T1 (hr) 2012-06-30
CA2526866A1 (en) 2004-12-09
KR101067586B1 (ko) 2011-09-27
JP4541361B2 (ja) 2010-09-08
KR20110050754A (ko) 2011-05-16
HRP20090281T1 (en) 2009-06-30
IS2722B (is) 2011-03-15
US20080249110A1 (en) 2008-10-09
ES2361485T3 (es) 2011-06-17
TW201024261A (en) 2010-07-01
CN1795174B (zh) 2011-09-28
SI2025670T1 (sl) 2011-06-30
HRP20110359T1 (hr) 2011-06-30
IL212371A0 (en) 2011-06-30
IL212265A0 (en) 2011-06-30
IL171928A0 (en) 2006-04-10
MY144483A (en) 2011-09-30
EP1656346B1 (en) 2009-03-18
EP2281815B1 (en) 2012-04-04
US7687535B2 (en) 2010-03-30
DK2281815T3 (da) 2012-06-18
SI1656346T1 (sl) 2009-08-31

Similar Documents

Publication Publication Date Title
BE2015C007I2 (xx)
BE2014C055I2 (xx)
BE2014C027I2 (xx)
BE2014C003I2 (xx)
BE2013C075I2 (xx)
BE2013C070I2 (xx)
BE2013C067I2 (xx)
BE2013C038I2 (xx)
BE2013C036I2 (xx)
BE2011C030I2 (xx)
JP2004054909A5 (xx)
IN2008CH00416A (xx)
JP2004163877A5 (xx)
BE2015C005I2 (xx)
BE2012C053I2 (xx)
JP2004213781A5 (xx)
JP2004219318A5 (xx)
JP2003330509A5 (xx)
JP2004001193A5 (xx)
JP2004065959A5 (xx)
JP2003235066A5 (xx)
JP2004216490A5 (xx)
JP2003338986A5 (xx)
JP2004215087A5 (xx)
CN300919864S (zh) 速度表

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160525